ArticleCirculation reports2026
Real-World Low-Density Lipoprotein Cholesterol Control After Transitioning From Evolocumab to Inclisiran.
Article in Circulation reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Inclisiran is a siRNA therapy that provides sustained reduction in low-density lipoprotein cholesterol (LDL-C) with twice-yearly dosing, but real-world data after switching from PCSK9 monoclonal antibodies remain limited. Methods and Results: We retrospectively analyzed 32 patients with coronary artery disease who transitioned from evolocumab to inclisiran. Median LDL-C was 27.0 mg/dL at baseline and remained stable at 3, 6, and 9 months (29.0, 30.5, and 29.5 mg/dL). Eight patients (25%) exceeded the LDL-C target (<70 mg/dL) at least once, more frequently among those with heterozygous familial hypercholesterolemia. Discontinuation occurred in 12.5%. Conclusions: Switching to inclisiran generally maintained LDL-C levels, although patients with familial hypercholesterolemia may require closer monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.